Trials / Recruiting
RecruitingNCT07447050
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
RiluzolE FOr Preventing Cognitive DysfUnction in Cancer PatientS Receiving Chemotherapy (REFOCUS)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- University of California, Irvine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase II single-arm, Phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining efficacy of riluzole in preventing cognitive dysfunction in subjects with cancer, who are receiving chemotherapy.
Conditions
- Breast Cancer
- Sarcoma
- Gastric (Stomach) Cancer
- Lung Cancer
- Head and Neck Cancer
- Colorectal Cancer
- Ovarian Cancer
- Liver Cancer
- Genitourinary Cancer
- Gynecologic Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Riluzole | Given PO |
| OTHER | Placebo | Given PO |
Timeline
- Start date
- 2025-12-23
- Primary completion
- 2027-12-31
- Completion
- 2028-12-31
- First posted
- 2026-03-03
- Last updated
- 2026-03-03
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07447050. Inclusion in this directory is not an endorsement.